Syndax Pharmaceuticals, Inc. (SNDX) Q4 FY25 Earnings Call

Dual launches are scaling, with frontline and IPF trials offering further expansion but adding clinical execution dependence. [20][43][58]

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-02
Length61 minutes
EPS$-0.78
EPS consensus$-0.64
Revenue$45.9M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26 · Q2 FY25

All SNDX earnings · Back to SNDX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.